Brain Tumours

Conclusions  Long-term data from EORTC 26951 and RTOG 9402 suggest RT + PCV as standard of care for patients with anaplastic glioma and 1p/19q co-deletion  NOA-04 data do not support an attempt to achieve comparable outcomes with monochemotherapy in patients with 1p/19q co-deleted tumors  RTOG 9802 long-term data suggest a benefit from RT/PCV compared to RT alone in the entire cohort of grade II tumors  PFS and OS gain in the RTOG 9802 dataset is most prominent in patients with oligodendroglial (= 1p/19q co- deleted ?) tumors  Whether PCV can be replaced by temozolomide remains unclear